bpc 157 carcinogenesis study Frontiers Recent advances and applications of

A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis

Big Pharma is winning the war for market share but theyre still losing patients to the underground

There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment

Decreased ZMIZ1 suppresses melanogenesis in vitiligo by regulating mTOR/AKT/GSK-3beta-mediated glucose uptake

International Classification of Diseases (ICD)

On the basis of these new preclinical results with LentiGlobin vector BB305 and the sustained positive outcome for a patient with the parental LentiGlobin vector HPV569 [170], both the ANSM (French) and the RAC/FDA (Recombinant DNA Advisory Committee/Federal Drug Administration, US) granted us approval, in 2013 and 2014, for three new clinical trials using LentiGlobin vector BB305 sponsored by the biotechnology company bluebird bio: (1) Trial NCT02151526 (HGB-205) in France, for both beta-thalassemia and sickle cell disease, (2) Trial NCT01745120 (HGB-204) at multiple centers in the US, Australia and Thailand, for beta-thalassemia, and (3) Trial NCT02140554 (HGB-206), at multiple centers in the US, for sickle cell disease